92 related articles for article (PubMed ID: 23594232)
1. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
[TBL] [Abstract][Full Text] [Related]
2. Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer.
Andersson E; Villabona L; Bergfeldt K; Carlson JW; Ferrone S; Kiessling R; Seliger B; Masucci GV
Cancer Immunol Immunother; 2012 Aug; 61(8):1243-53. PubMed ID: 22258792
[TBL] [Abstract][Full Text] [Related]
3. The clinical and prognostic correlation of HRNPM and SLC1A5 in pathogenesis and prognosis in epithelial ovarian cancer.
Bjersand K; Seidal T; Sundström-Poromaa I; Åkerud H; Skirnisdottir I
PLoS One; 2017; 12(6):e0179363. PubMed ID: 28609484
[TBL] [Abstract][Full Text] [Related]
4. Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.
Köbel M; Madore J; Ramus SJ; Clarke BA; Pharoah PD; Deen S; Bowtell DD; Odunsi K; Menon U; Morrison C; Lele S; Bshara W; Sucheston L; Beckmann MW; Hein A; Thiel FC; Hartmann A; Wachter DL; Anglesio MS; Høgdall E; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Fogarty ZC; Vierkant RA; Liu S; Cho S; Nelson G; Ghatage P; Gentry-Maharaj A; Gayther SA; Benjamin E; Widschwendter M; Intermaggio MP; Rosen B; Bernardini MQ; Mackay H; Oza A; Shaw P; Jimenez-Linan M; Driver KE; Alsop J; Mack M; Koziak JM; Steed H; Ewanowich C; DeFazio A; Chenevix-Trench G; Fereday S; Gao B; Johnatty SE; George J; Galletta L; ; Goode EL; Kjær SK; Huntsman DG; Fasching PA; Moysich KB; Brenton JD; Kelemen LE
Br J Cancer; 2014 Dec; 111(12):2297-307. PubMed ID: 25349970
[TBL] [Abstract][Full Text] [Related]
5. Expression of preoperative KISS1 gene in tumor tissue with epithelial ovarian cancer and its prognostic value.
Cao F; Chen L; Liu M; Lin W; Ji J; You J; Qiao F; Liu H
Medicine (Baltimore); 2016 Nov; 95(46):e5296. PubMed ID: 27861355
[TBL] [Abstract][Full Text] [Related]
6. Comparison of prognoses according to non-positive and positive spectrin αII expression detected immunohistochemically in epithelial ovarian carcinoma: a retrospective study.
Maeda O; Miyata-Takata T; Shibata K; Kajiyama H; Mizuno M; Tamakoshi K; Shimoyama Y; Nakamura S; Kikkawa F
Cancer Med; 2016 Jun; 5(6):1081-92. PubMed ID: 26993048
[TBL] [Abstract][Full Text] [Related]
7. Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.
Martins FC; Couturier DL; Paterson A; Karnezis AN; Chow C; Nazeran TM; Odunsi A; Gentry-Maharaj A; Vrvilo A; Hein A; Talhouk A; Osorio A; Hartkopf AD; Brooks-Wilson A; DeFazio A; Fischer A; Hartmann A; Hernandez BY; McCauley BM; Karpinskyj C; de Sousa CB; Høgdall C; Tiezzi DG; Herpel E; Taran FA; Modugno F; Keeney G; Nelson G; Steed H; Song H; Luk H; Benitez J; Alsop J; Koziak JM; Lester J; Rothstein JH; de Andrade JM; Lundvall L; Paz-Ares L; Robles-Díaz L; Wilkens LR; Garcia MJ; Intermaggio MP; Alcaraz ML; Brett MA; Beckmann MW; Jimenez-Linan M; Anglesio M; Carney ME; Schneider M; Traficante N; Pejovic N; Singh N; Le N; Sinn P; Ghatage P; Erber R; Edwards R; Vierkant R; Ness RB; Leung S; Orsulic S; Brucker SY; Kaufmann SH; Fereday S; Gayther S; Winham SJ; Kommoss S; Pejovic T; Longacre TA; McGuire V; Rhenius V; Sieh W; Shvetsov YB; Whittemore AS; Staebler A; Karlan BY; Rodriguez-Antona C; Bowtell DD; Goode EL; Høgdall E; Candido Dos Reis FJ; Gronwald J; Chang-Claude J; Moysich KB; Kelemen LE; Cook LS; Goodman MT; Fasching PA; Crawford R; Deen S; Menon U; Huntsman DG; Köbel M; Ramus SJ; Pharoah PDP; Brenton JD
Br J Cancer; 2020 Sep; 123(5):793-802. PubMed ID: 32555365
[TBL] [Abstract][Full Text] [Related]
8. BRCA1 expression, proliferative and apoptotic activities in ovarian epithelial inclusions.
Wang Y; Wang Y; Wei L; Hong S; Zhao M; Zhang X; Zheng W
J Ovarian Res; 2017 Mar; 10(1):12. PubMed ID: 28270171
[TBL] [Abstract][Full Text] [Related]
9. Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors.
Beeghly-Fadiel A; Wilson AJ; Keene S; El Ramahi M; Xu S; Marnett LJ; Fadare O; Crispens MA; Khabele D
J Ovarian Res; 2018 Feb; 11(1):17. PubMed ID: 29482584
[TBL] [Abstract][Full Text] [Related]
10. Time to diagnosis of Type I or II invasive epithelial ovarian cancers: a multicentre observational study using patient questionnaire and primary care records.
Lim A; Mesher D; Gentry-Maharaj A; Balogun N; Widschwendter M; Jacobs I; Sasieni P; Menon U
BJOG; 2016 May; 123(6):1012-20. PubMed ID: 26032603
[TBL] [Abstract][Full Text] [Related]
11. Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer.
Block MS; Charbonneau B; Vierkant RA; Fogarty Z; Bamlet WR; Pharoah PD; ; ; ; Rossing MA; Cramer D; Pearce CL; Schildkraut J; Menon U; Kjaer SK; Levine DA; Gronwald J; Culver HA; Whittemore AS; Karlan BY; Lambrechts D; Wentzensen N; Kupryjanczyk J; Chang-Claude J; Bandera EV; Hogdall E; Heitz F; Kaye SB; Fasching PA; Campbell I; Goodman MT; Pejovic T; Bean YT; Hays LE; Lurie G; Eccles D; Hein A; Beckmann MW; Ekici AB; Paul J; Brown R; Flanagan JM; Harter P; du Bois A; Schwaab I; Hogdall CK; Lundvall L; Olson SH; Orlow I; Paddock LE; Rudolph A; Eilber U; Dansonka-Mieszkowska A; Rzepecka IK; Ziolkowska-Seta I; Brinton LA; Yang H; Garcia-Closas M; Despierre E; Lambrechts S; Vergote I; Walsh CS; Lester J; Sieh W; McGuire V; Rothstein JH; Ziogas A; Lubiński J; Cybulski C; Menkiszak J; Jensen A; Gayther SA; Ramus SJ; Gentry-Maharaj A; Berchuck A; Wu AH; Pike MC; Van Den Berg D; Terry KL; Vitonis AF; Ramirez SM; Rider DN; Knutson KL; Sellers TA; Phelan CM; Doherty JA; Johnatty SE; deFazio A; Song H; Tyrer J; Kalli KR; Fridley BL; Cunningham JM; Goode EL
Cancer Epidemiol Biomarkers Prev; 2014 Jul; 23(7):1421-7. PubMed ID: 24740199
[TBL] [Abstract][Full Text] [Related]
12. Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer.
Abdel-Fatah TM; Russell R; Albarakati N; Maloney DJ; Dorjsuren D; Rueda OM; Moseley P; Mohan V; Sun H; Abbotts R; Mukherjee A; Agarwal D; Illuzzi JL; Jadhav A; Simeonov A; Ball G; Chan S; Caldas C; Ellis IO; Wilson DM; Madhusudan S
Mol Oncol; 2014 Oct; 8(7):1326-38. PubMed ID: 24880630
[TBL] [Abstract][Full Text] [Related]
13. SSRI use and clinical outcomes in epithelial ovarian cancer.
Christensen DK; Armaiz-Pena GN; Ramirez E; Matsuo K; Zimmerman B; Zand B; Shinn E; Goodheart MJ; Bender D; Thaker PH; Ahmed A; Penedo FJ; DeGeest K; Mendez L; Domann F; Sood AK; Lutgendorf SK
Oncotarget; 2016 May; 7(22):33179-91. PubMed ID: 27121207
[TBL] [Abstract][Full Text] [Related]
14. Smoking and risk of ovarian cancer by histological subtypes: an analysis among 300 000 Norwegian women.
Licaj I; Jacobsen BK; Selmer RM; Maskarinec G; Weiderpass E; Gram IT
Br J Cancer; 2017 Jan; 116(2):270-276. PubMed ID: 27959888
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Survival Among Histological Subtypes in Advanced Epithelial Ovarian Cancer: Population-Based Study Using the Surveillance, Epidemiology, and End Results Database.
Yang SP; Su HL; Chen XB; Hua L; Chen JX; Hu M; Lei J; Wu SG; Zhou J
JMIR Public Health Surveill; 2021 Nov; 7(11):e25976. PubMed ID: 34787583
[TBL] [Abstract][Full Text] [Related]
16. A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients.
Zhang M; He Y; Sun X; Li Q; Wang W; Zhao A; Di W
J Ovarian Res; 2014 Feb; 7():19. PubMed ID: 24507759
[TBL] [Abstract][Full Text] [Related]
17. Pre-operative plasma VEGF-C levels portend recurrence in epithelial ovarian cancer patients and is a bankable prognostic marker even in the initial assessment of a patient.
Bhaskari J; Bhagat R; Shilpa V; Premalata CS; Krishnamoorthy L
J Ovarian Res; 2024 Apr; 17(1):77. PubMed ID: 38594780
[TBL] [Abstract][Full Text] [Related]
18. Investigating the Spatial Distribution of Proliferating Cells in Primary Ovarian Cancers.
Hegazi MAAA; Pasqualini F; Taverna G; Bresalier RS; Chiriva-Internati M; Grizzi F
Discov Med; 2024 Mar; 36(182):632-645. PubMed ID: 38531804
[TBL] [Abstract][Full Text] [Related]
19. Infiltrative pattern of invasion is independently associated with shorter survival and desmoplastic stroma markers FAP and THBS2 in mucinous ovarian carcinoma.
Köbel M; Kang EY; Lee S; Terzic T; Karnezis AN; Ghatage P; Woo L; Lee CH; Meagher NS; Ramus SJ; Gorringe KL
Histopathology; 2024 Jun; 84(7):1095-1110. PubMed ID: 38155475
[TBL] [Abstract][Full Text] [Related]
20. Molecular Pathology of Ovarian Epithelial Neoplasms: Predictive, Prognostic, and Emerging Biomarkers.
Ordulu Z; Watkins J; Ritterhouse LL
Clin Lab Med; 2024 Jun; 44(2):199-219. PubMed ID: 38821641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
